Ana Luzarraga Aznar, Vicente Bebia, Natalia Rodriguez Gomez-Hidalgo, Carlos López-Gil, Marta Miguez, Eva Colas, Asunción Pérez-Benavente, Antonio Gil-Moreno, Silvia Cabrera
{"title":"子宫内膜癌的分子谱：我们能否预测淋巴结状态？系统回顾与荟萃分析","authors":"Ana Luzarraga Aznar, Vicente Bebia, Natalia Rodriguez Gomez-Hidalgo, Carlos López-Gil, Marta Miguez, Eva Colas, Asunción Pérez-Benavente, Antonio Gil-Moreno, Silvia Cabrera","doi":"10.1007/s12094-024-03401-y","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Molecular classification of endometrial cancer (EC) has become a promising information to tailor preoperatively the surgical treatment. We aimed to evaluate the rate of lymph node metastases (LNM) in patients with EC according to molecular profile.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A systematic review and meta-analysis were performed according to PRISMA guidelines by searching in two major electronic databases (PubMed and Scopus), including original articles reporting lymph node metastases according to the molecular classification of EC as categorized in the ESGO-ESMO-ESP guidelines.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Fifteen studies enrolling 3056 patients were included. Pooled prevalence LNM when considering only patients undergoing lymph node assessment was 4% for POLE-mutated (95%CI: 0-12%), 22% for no specific molecular profile (95% CI: 9-39%), 23% for Mismatch repair-deficiency (95%CI: 10-40%) and 31% for p53-abnormal (95%CI: 24-39%).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>The presence of LNM seems to be influenced by molecular\nclassification. P53-abnormal group presents the highest rate of nodal involvement, and POLE-mutated the lowest.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Molecular profile in endometrial carcinoma: can we predict the lymph node status? A systematic review and meta-analysis\",\"authors\":\"Ana Luzarraga Aznar, Vicente Bebia, Natalia Rodriguez Gomez-Hidalgo, Carlos López-Gil, Marta Miguez, Eva Colas, Asunción Pérez-Benavente, Antonio Gil-Moreno, Silvia Cabrera\",\"doi\":\"10.1007/s12094-024-03401-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h3 data-test=\\\"abstract-sub-heading\\\">Purpose</h3><p>Molecular classification of endometrial cancer (EC) has become a promising information to tailor preoperatively the surgical treatment. We aimed to evaluate the rate of lymph node metastases (LNM) in patients with EC according to molecular profile.</p><h3 data-test=\\\"abstract-sub-heading\\\">Methods</h3><p>A systematic review and meta-analysis were performed according to PRISMA guidelines by searching in two major electronic databases (PubMed and Scopus), including original articles reporting lymph node metastases according to the molecular classification of EC as categorized in the ESGO-ESMO-ESP guidelines.</p><h3 data-test=\\\"abstract-sub-heading\\\">Results</h3><p>Fifteen studies enrolling 3056 patients were included. Pooled prevalence LNM when considering only patients undergoing lymph node assessment was 4% for POLE-mutated (95%CI: 0-12%), 22% for no specific molecular profile (95% CI: 9-39%), 23% for Mismatch repair-deficiency (95%CI: 10-40%) and 31% for p53-abnormal (95%CI: 24-39%).</p><h3 data-test=\\\"abstract-sub-heading\\\">Conclusions</h3><p>The presence of LNM seems to be influenced by molecular\\nclassification. P53-abnormal group presents the highest rate of nodal involvement, and POLE-mutated the lowest.</p>\",\"PeriodicalId\":10166,\"journal\":{\"name\":\"Clinical and Translational Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Translational Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s12094-024-03401-y\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12094-024-03401-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Molecular profile in endometrial carcinoma: can we predict the lymph node status? A systematic review and meta-analysis
Purpose
Molecular classification of endometrial cancer (EC) has become a promising information to tailor preoperatively the surgical treatment. We aimed to evaluate the rate of lymph node metastases (LNM) in patients with EC according to molecular profile.
Methods
A systematic review and meta-analysis were performed according to PRISMA guidelines by searching in two major electronic databases (PubMed and Scopus), including original articles reporting lymph node metastases according to the molecular classification of EC as categorized in the ESGO-ESMO-ESP guidelines.
Results
Fifteen studies enrolling 3056 patients were included. Pooled prevalence LNM when considering only patients undergoing lymph node assessment was 4% for POLE-mutated (95%CI: 0-12%), 22% for no specific molecular profile (95% CI: 9-39%), 23% for Mismatch repair-deficiency (95%CI: 10-40%) and 31% for p53-abnormal (95%CI: 24-39%).
Conclusions
The presence of LNM seems to be influenced by molecular
classification. P53-abnormal group presents the highest rate of nodal involvement, and POLE-mutated the lowest.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
